Clinical trial readout dates for Xenon Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.
| Phase 3 Azetukalner Major Depressive Disorder · NCT06922110 | January 2027 Ongoing |
| Phase 3 XEN1101 Primary Generalized Tonic-Clonic Seizures · NCT05667142 | April 2027 Recruiting |
| Phase 3 Azetukalner Major Depressive Disorder · NCT07076407 | May 2027 Ongoing |
| Phase 3 XEN1101 Focal Onset Seizures · NCT05716100 | January 2028 Recruiting |
| Phase 3 Azetukalner Bipolar Disorder; Bipolar Depression · NCT07172516 | June 2028 Ongoing |
| Phase 3 Azetukalner Bipolar Depression; Bipolar I Disorder · NCT07217860 | June 2029 Ongoing |
| Phase 3 XEN1101 Focal Epilepsy; Tonic-Clonic Seizures · NCT05718817 | April 2033 Enrolling |
Xenon Pharmaceuticals Inc. reported $1.15B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $110M; at that rate the cash would last about 10 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-09 |